SEMAX 10 mg — Neurobiology & Cognitive Research
Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH 4–7). It is studied in preclinical research for its potential effects on neurotrophic signaling, neuronal protection, learning and memory pathways, and cellular responses to neurological stress.
Research has examined Semax in relation to BDNF-associated signaling, neurotransmitter regulation, neuroplasticity, and mechanisms involved in cognitive and neurological function.
For laboratory and research use only. Not for human consumption.
SEMAX 10 mg — Neurobiology & Cognitive Research
Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH 4–7). It is studied in preclinical research for its potential effects on neurotrophic signaling, neuronal protection, learning and memory pathways, and cellular responses to neurological stress.
Research has examined Semax in relation to BDNF-associated signaling, neurotransmitter regulation, neuroplasticity, and mechanisms involved in cognitive and neurological function.
For laboratory and research use only. Not for human consumption.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
on orders over $200
plain and unbranded packaging
256-bit SSL
Not a researcher? Exit
